中国药房2026，Vol.37Issue(16)：2202-2207,6.DOI:10.6039/j.issn.1001-0408.2026.16.21
肠促胰素类药物在减重中的临床应用及新药研究进展
Clinical application of incretin-based drugs in weight reduction and research progress of novel agents
摘要
Abstract
Incretin-based drugs have demonstrated significant clinical value in weight management and the treatment of metabolic diseases by mimicking or enhancing endogenous incretin signaling.These agents primarily target multiple receptors including glucagon-like peptide-1,glucose-dependent insulinotropic polypeptide,and glucagon,exerting weight-reducing effects through multiple mechanisms such as central appetite regulation,gastrointestinal function modulation,and peripheral metabolic improvement,while further ameliorating blood glucose,blood lipids,fatty liver,and cardiorenal metabolic risks.This review focuses on incretin-based drugs,systematically summarizing the key clinical application points and relevant research progress of domestically marketed and investigational candidate drugs in the field of weight reduction.Available evidence indicates that semaglutide and tirzepatide demonstrate substantial weight reduction with multiple metabolic benefits;domestic innovative drugs represented by mazdutide and ecnoglutide also exhibit favorable weight-reducing effects and safety profiles.Regarding safety,these agents are generally well-tolerated,with the most common adverse reactions being mild-to-moderate gastrointestinal events,while potential risks including gallbladder events,pancreatitis,and mood changes require attention.In special populations,individualized assessment is warranted for use in children,elderly people,and pregnant women.Future research should focus on the screening of predictive biomarkers for efficacy,the development of long-acting oral formulations,and the accumulation of long-term safety follow-up data.关键词
肠促胰素类药物/减重/肥胖症/代谢性疾病Key words
incretin-based drugs/weight reduction/obesity/metabolic diseases分类
医药卫生引用本文复制引用
罗成思,高蕊,朱艳娇,吴希超,何帅,宋智颖,李安安,周芃霖,李妍..肠促胰素类药物在减重中的临床应用及新药研究进展[J].中国药房,2026,37(16):2202-2207,6.基金项目
山东省药品临床综合评价项目(No.2024YZ002) （No.2024YZ002）
